BrainStorm Cell Therapeutics Inc. Financial Results Overview
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a pioneer in the adult stem cell therapeutics field for neurodegenerative diseases, has recently announced its financial outcome for the third quarter, marking significant progress in its operations.
Chaim Lebovits, the President and CEO of BrainStorm, highlighted the steady efforts made toward stabilizing its financial foundation while preparing for the Phase 3b clinical trial of NurOwn. This trial aims to produce essential data that will assist in a future Biologics License Application (BLA) submission. The FDA has granted clearance for the study, which reflects BrainStorm's unwavering commitment to improving the well-being of individuals battling ALS.
Recent Developments in Clinical Trials
BrainStorm has embarked on key pre-initiation activities for the Phase 3b clinical trial of NurOwn, known as the ENDURANCE study. This trial expects enrollment of around 200 participants at prestigious ALS centers. The first part of the trial will last 24 weeks, followed by a 24-week open-label extension, enabling an in-depth analysis of long-term safety and efficacy.
Regulatory engagement remains a top priority as the company collaborates closely with clinical sites and manufacturing partners, ensuring support for trial operations. Beyond this structured study, representatives from the ALS community have submitted a Citizen Petition seeking a renewed regulatory review of NurOwn, highlighting the ongoing enthusiasm surrounding its therapeutic potential.
Financial Highlights for Q3
Regarding financial metrics, as of September 30, 2025, BrainStorm's cash, cash equivalents, and restricted cash amounted to approximately $0.23 million. The R&D expenditures for the third quarter decreased to $0.9 million compared to $1 million in the previous year. Similarly, the company reported general and administrative expenses of about $1.1 million against $2 million for the same quarter last year.
Despite ongoing challenges, BrainStorm's net loss for the quarter narrowed to approximately $2.1 million, compared to the $2.7 million reported in the same quarter of 2024. This exemplifies the company's diligent efforts in financial management.
About NurOwn Technology
BrainStorm’s NurOwn technology is recognized as an innovative therapeutic strategy leveraging MSC-NTF (mesenchymal stem cells secreting neurotrophic factors). This approach targets critical pathways associated with neurodegenerative conditions such as ALS. The development and transformation of MSCs into MSC-NTF cells is conducted through a proprietary process that enhances their neuroprotective capabilities.
With Orphan Drug designation from both the FDA and the European Medicines Agency, NurOwn stands as a focal point of BrainStorm's clinical endeavors. Previous trials have yielded valuable insights into ALS, including biomarkers and pharmacogenomic responses. These data are crucial as the company seeks regulatory approvals for its therapies.
The Path Forward for BrainStorm
BrainStorm is gearing up for a conference call and webcast to further discuss advancements in the NurOwn Phase 3 program, as the ALS community and investors eagerly await updates. The forthcoming public engagement demonstrates the company’s commitment to transparency and collaboration.
Furthermore, BrainStorm is expanding its portfolio by developing an exclusive exosome-based platform, aimed at delivering therapeutic proteins and nucleic acids in regenerative medicine. This step bolsters the company's intellectual property positioning, further enhancing its innovative approach.
Conclusion
In conclusion, BrainStorm Cell Therapeutics Inc. is making significant strides in its financial and clinical journey. As the company prepares for future trials and engages with the medical community, its commitment to transforming the landscape for ALS treatment remains evident. The integration of innovative technologies like NurOwn underscores BrainStorm's potential to positively impact the lives of those afflicted with neurodegenerative diseases.
Frequently Asked Questions
What recent financial results did BrainStorm announce?
BrainStorm reported a net loss of approximately $2.1 million for the third quarter, a decrease from $2.7 million in the same quarter of the previous year.
What is NurOwn and its significance?
NurOwn is BrainStorm's leading investigational therapy for ALS, utilizing mesenchymal stem cells that secrete neurotrophic factors to target neurodegenerative pathways.
What trial is BrainStorm currently preparing for?
BrainStorm is preparing for the Phase 3b ENDURANCE study, which is expected to enroll about 200 participants and assess long-term impacts of NurOwn.
How has BrainStorm's financial health changed over the last year?
BrainStorm has improved its financial metrics, with reduced operating losses and ongoing efforts to manage expenses effectively.
What are the future plans for BrainStorm?
The company plans to host an investor conference call and continue development of NurOwn and its exosome technology platform while actively engaging with the ALS community.
